Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Keros Therapeutics (KROS) FCF Margin (2019 - 2025)

Historic FCF Margin for Keros Therapeutics (KROS) over the last 6 years, with Q3 2025 value amounting to 21.86%.

  • Keros Therapeutics' FCF Margin rose 79821600.0% to 21.86% in Q3 2025 from the same period last year, while for Sep 2025 it was 35.3%, marking a year-over-year increase of 219251600.0%. This contributed to the annual value of 4585.92% for FY2024, which is 795015000.0% up from last year.
  • Keros Therapeutics' FCF Margin amounted to 21.86% in Q3 2025, which was up 79821600.0% from 167.01% recorded in Q2 2025.
  • Keros Therapeutics' 5-year FCF Margin high stood at 1071500.0% for Q1 2021, and its period low was 431650.0% during Q3 2023.
  • For the 5-year period, Keros Therapeutics' FCF Margin averaged around 33124.33%, with its median value being 1521.93% (2024).
  • Its FCF Margin has fluctuated over the past 5 years, first plummeted by 2000000000bps in 2022, then skyrocketed by 2000000000bps in 2024.
  • Keros Therapeutics' FCF Margin (Quarter) stood at 110.19% in 2021, then skyrocketed by 92bps to 8.74% in 2022, then plummeted by -207824bps to 18181.82% in 2023, then soared by 92bps to 1521.93% in 2024, then surged by 101bps to 21.86% in 2025.
  • Its FCF Margin was 21.86% in Q3 2025, compared to 167.01% in Q2 2025 and 76.03% in Q1 2025.